Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,549 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Development of a two-part strategy to identify a therapeutic human bispecific antibody that inhibits IgE receptor signaling.
Jackman J, Chen Y, Huang A, Moffat B, Scheer JM, Leong SR, Lee WP, Zhang J, Sharma N, Lu Y, Iyer S, Shields RL, Chiang N, Bauer MC, Wadley D, Roose-Girma M, Vandlen R, Yansura DG, Wu Y, Wu LC. Jackman J, et al. Among authors: iyer s. J Biol Chem. 2010 Jul 2;285(27):20850-9. doi: 10.1074/jbc.M110.113910. Epub 2010 May 5. J Biol Chem. 2010. PMID: 20444694 Free PMC article.
Anti-BR3 antibodies: a new class of B-cell immunotherapy combining cellular depletion and survival blockade.
Lin WY, Gong Q, Seshasayee D, Lin Z, Ou Q, Ye S, Suto E, Shu J, Lee WP, Lee CW, Fuh G, Leabman M, Iyer S, Howell K, Gelzleichter T, Beyer J, Danilenko D, Yeh S, DeForge LE, Ebens A, Thompson JS, Ambrose C, Balazs M, Starovasnik MA, Martin F. Lin WY, et al. Among authors: iyer s. Blood. 2007 Dec 1;110(12):3959-67. doi: 10.1182/blood-2007-04-088088. Epub 2007 Aug 8. Blood. 2007. PMID: 17687108 Free article.
A T-cell engaging bispecific antibody with a tumor-selective bivalent folate receptor alpha binding arm for the treatment of ovarian cancer.
Avanzino BC, Prabhakar K, Dalvi P, Hartstein S, Kehm H, Balasubramani A, Boudreau AA, Buelow B, Chang K, Davison LM, Iyer S, Kalwit V, Lewis Wilson K, Malik-Chaudhry HK, Pierson W, Pineda G, Rangaswamy US, Saiganesh S, Schellenberger U, Ugamraj HS, Yabut RD, Buelow R, Chapman J, Trinklein ND, Harris KE. Avanzino BC, et al. Among authors: iyer s. Oncoimmunology. 2022 Aug 20;11(1):2113697. doi: 10.1080/2162402X.2022.2113697. eCollection 2022. Oncoimmunology. 2022. PMID: 36016696 Free PMC article.
Efficient tumor killing and minimal cytokine release with novel T-cell agonist bispecific antibodies.
Trinklein ND, Pham D, Schellenberger U, Buelow B, Boudreau A, Choudhry P, Clarke SC, Dang K, Harris KE, Iyer S, Jorgensen B, Pratap PP, Rangaswamy US, Ugamraj HS, Vafa O, Wiita AP, van Schooten W, Buelow R, Force Aldred S. Trinklein ND, et al. Among authors: iyer s. MAbs. 2019 May/Jun;11(4):639-652. doi: 10.1080/19420862.2019.1574521. Epub 2019 Feb 20. MAbs. 2019. PMID: 30698484 Free PMC article.
Attenuating CD3 affinity in a PSMAxCD3 bispecific antibody enables killing of prostate tumor cells with reduced cytokine release.
Dang K, Castello G, Clarke SC, Li Y, Balasubramani A, Boudreau A, Davison L, Harris KE, Pham D, Sankaran P, Ugamraj HS, Deng R, Kwek S, Starzinski A, Iyer S, van Schooten W, Schellenberger U, Sun W, Trinklein ND, Buelow R, Buelow B, Fong L, Dalvi P. Dang K, et al. Among authors: iyer s. J Immunother Cancer. 2021 Jun;9(6):e002488. doi: 10.1136/jitc-2021-002488. J Immunother Cancer. 2021. PMID: 34088740 Free PMC article.
2,549 results